ESPR - NASDAQ
Esperion Therapeutics, Inc.
$3.14
+0.32%Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
At a Glance
Live SnapshotNo Dividend Yield Data
ESPR has not reported any dividend yield values in the available annual periods.
No Dividend Payout Ratio Data
ESPR has not reported any dividend payout ratio values in the available annual periods.
No Net Dividends Paid Data
ESPR has not reported any net dividends paid values in the available annual periods.
Esperion Therapeutics, Inc. Dividend History
ESPR Dividend Payment History
| Declaration | Ex-Date | Payment Date | Dividend | Adjusted | Frequency | Growth |
|---|---|---|---|---|---|---|
| No dividend payment history available | ||||||
Esperion Therapeutics, Inc. Payout Ratio Analysis
Dividend Sustainability Analysis
Payout Ratio
Conservative payout with excellent safety margin. Company retains significant earnings for growth, acquisitions, or building cash reserves. Dividend is highly sustainable.
FCF Payout Ratio
Negative free cash flow while paying dividends is a major red flag. Company burning cash and cannot sustain dividend without external financing.
Sustainability
Dividend appears unsustainable based on current metrics. High probability of reduction or elimination. Proceed with caution.
Related Guides
Continue your ESPR research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.